Ionis Pharmaceuticals Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Ionis Pharmaceuticals Inc 公司

Ionis Pharmaceuticals, Inc. 从事核糖核酸 (RNA) 靶向治疗。该公司有五种已上市药物和一条产品线，涉及神经病学、心脏病学和其他患者需求高的领域。该公司有九种药物处于 III 期开发阶段，还有多种其他药物处于早期和中期开发阶段。该公司的产品包括 SPINRAZA、QALSODY、WAINUA、TEGSEDI 和 WAYLIVRA。SPINRAZA 用于治疗脊髓性肌萎缩症 (SMA) 患者，这是一种进行性、使人衰弱且通常致命的遗传疾病。QALSODY 是一种反义药物，用于治疗超氧化物歧化酶 1 肌萎缩侧索硬化症 (SOD1-ALS) 的成年患者，这是一种罕见的神经退行性疾病，会导致运动神经元逐渐丧失并导致死亡。 WAINUA 是一种自行注射的皮下配体结合反义 (LICA) 药物，用于治疗患有遗传性转甲状腺素介导的淀粉样变性多发性神经病 (ATTRv-PN) 的成年人。

Ionis Pharmaceuticals Inc简介



公司代码IONS

公司名称Ionis Pharmaceuticals Inc

上市日期May 17, 1991

CEODr. Brett P. Monia, Ph.D.

员工数量1069

证券类型Ordinary Share

年结日May 17

公司地址2855 Gazelle Court

城市CARLSBAD

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编92010

电话17609319200

网址https://www.ionis.com/

公司代码IONS

上市日期May 17, 1991

CEODr. Brett P. Monia, Ph.D.

Ionis Pharmaceuticals Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Brett P. Monia, Ph.D.

Chief Executive Officer, Director

180.01K

--

Dr. Spencer R. Berthelsen, M.D.

Independent Director

156.08K

+2.68%

Ms. Elizabeth L. Hougen

Chief Financial Officer, Executive Vice President - Finance

110.50K

--

Dr. Richard S. Geary, Ph.D.

Executive Vice President, Chief Development Officer

79.66K

-11.15%

Mr. Patrick R. O'Neil, Esq.

Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary

57.13K

--

Mr. Brian Birchler

Executive Vice President, Chief Business Officer

56.83K

+0.29%

Mr. Eugene Schneider, M.D.

Executive Vice President, Chief Clinical Development and Operations Officer

47.47K

--

Dr. Eric E. Swayze, Ph.D.

Executive Vice President - Research

37.42K

--

Dr. Joseph Loscalzo, M.D., Ph.D.

Independent Chairman of the Board

36.33K

--

Ms. Shannon L. Devers

Chief Human Resources Officer, Executive Vice President

15.94K

--

名称

名称/职务

职务

持股

持股变动

Dr. Brett P. Monia, Ph.D.

Chief Executive Officer, Director

180.01K

--

Dr. Spencer R. Berthelsen, M.D.

Independent Director

156.08K

+2.68%

Ms. Elizabeth L. Hougen

Chief Financial Officer, Executive Vice President - Finance

110.50K

--

Dr. Richard S. Geary, Ph.D.

Executive Vice President, Chief Development Officer

79.66K

-11.15%

Mr. Patrick R. O'Neil, Esq.

Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary

57.13K

--

Mr. Brian Birchler

Executive Vice President, Chief Business Officer

56.83K

+0.29%

收入明细

单位: USD更新时间: 3月4日周二

FY2020

FY2019

业务USD

名称

营收

占比

R&D revenue under collaborative agreements

364.56M

49.99%

SPINRAZA royalties

286.58M

39.30%

Product sales, net

70.00M

9.60%

Licensing and other Royalty revenue

8.12M

1.11%

暂无数据

业务

地区

业务USD

名称

营收

占比

R&D revenue under collaborative agreements

364.56M

49.99%

SPINRAZA royalties

286.58M

39.30%

Product sales, net

70.00M

9.60%

Licensing and other Royalty revenue

8.12M

1.11%

股东统计

更新时间: 8月23日周六

持股股东

股东类型

持股股东

占比

Fidelity Management & Research Company LLC

14.83%

The Vanguard Group, Inc.

10.47%

T. Rowe Price Investment Management, Inc.

10.07%

Capital World Investors

7.87%

BlackRock Institutional Trust Company, N.A.

5.47%

其他

51.29%

持股股东

占比

Fidelity Management & Research Company LLC

14.83%

The Vanguard Group, Inc.

10.47%

T. Rowe Price Investment Management, Inc.

10.07%

Capital World Investors

7.87%

BlackRock Institutional Trust Company, N.A.

5.47%

其他

51.29%

股东类型

持股股东

占比

Investment Advisor

70.88%

Investment Advisor/Hedge Fund

17.08%

Hedge Fund

16.01%

Research Firm

2.02%

Pension Fund

1.13%

Individual Investor

0.78%

Bank and Trust

0.68%

Sovereign Wealth Fund

0.28%

Family Office

0.02%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

790

172.50M

108.22%

-7.29M

2025Q2

801

185.40M

116.34%

+8.33M

2025Q1

826

174.18M

109.45%

-1.97M

2024Q4

819

166.51M

104.84%

-2.69M

2024Q3

814

162.85M

103.55%

+6.60M

2024Q2

810

149.96M

102.64%

-3.87M

2024Q1

792

148.14M

101.63%

-5.27M

2023Q4

782

147.15M

102.53%

-3.26M

2023Q3

763

145.13M

101.24%

-1.40M

2023Q2

770

142.08M

99.29%

+364.04K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Fidelity Management & Research Company LLC

23.64M

14.83%

+29.41K

+0.12%

Jun 30, 2025

The Vanguard Group, Inc.

16.68M

10.47%

+329.29K

+2.01%

Jun 30, 2025

T. Rowe Price Investment Management, Inc.

16.05M

10.07%

-126.81K

-0.78%

Jun 30, 2025

Capital World Investors

12.54M

7.87%

+178.19K

+1.44%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

8.73M

5.47%

-171.64K

-1.93%

Jun 30, 2025

Bellevue Asset Management AG

7.85M

4.93%

--

Jun 30, 2025

Wellington Management Company, LLP

6.35M

3.98%

-2.07M

-24.60%

Jun 30, 2025

Deep Track Capital LP

4.89M

3.07%

+327.34K

+7.17%

Jun 30, 2025

State Street Global Advisors (US)

4.53M

2.84%

-314.74K

-6.50%

Jun 30, 2025

Two Sigma Investments, LP

4.46M

2.8%

+678.11K

+17.95%

Jun 30, 2025

持股ETF



更新时间: 9月6日周六

机构名称

占比

iShares Russell 3000 ETF

0%

iShares Russell 1000 Value ETF

0%

Fidelity MSCI Health Care Index ETF

0%

VanEck Morningstar SMID Moat ETF

0%

Fidelity Nasdaq Composite Index ETF

0%

JPMorgan BetaBuilders US Mid Cap Equity ETF

0%

iShares Russell 2500 ETF

0%

iShares US Small-Cap Equity Factor ETF

0%

Schwab U.S. Broad Market ETF

0%

iShares MSCI USA Small-Cap Min Vol Factor ETF

0%

iShares Russell 3000 ETF

占比0%

iShares Russell 1000 Value ETF

占比0%

Fidelity MSCI Health Care Index ETF

占比0%

VanEck Morningstar SMID Moat ETF

占比0%

Fidelity Nasdaq Composite Index ETF

占比0%

JPMorgan BetaBuilders US Mid Cap Equity ETF

占比0%

iShares Russell 2500 ETF

占比0%

iShares US Small-Cap Equity Factor ETF

占比0%

Schwab U.S. Broad Market ETF

占比0%

iShares MSCI USA Small-Cap Min Vol Factor ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据